Lv3
332 积分 2026-01-30 加入
Trends in the landscape of clinical trials of innovative drugs in China since 2015
1个月前
已完结
Regulation of Real‐World Evidence in Rare Diseases in the MENA Region: A Review of Current Guidelines Compared to Global Frameworks
1个月前
已完结
Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing
1个月前
已完结
Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission
1个月前
已完结
Navigating Regulatory Pathways for Access to Innovative Medicines in Tunisia
1个月前
已完结
Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines
1个月前
已关闭
Limited Progression of Nuclear Sclerosis after Lens-Sparing Vitrectomy in Proliferative Diabetic Retinopathy Eyes: A Real-World Investigation with Scheimpflug Lens Densitometry
2个月前
已关闭
Reform of China’s Medical Insurance Payment Methods: Progress, Challenges, and Pathways for Deepening
3个月前
已完结
Who Contracts on Diagnosis Related Groups and How Are They Priced? Evidence From Hospital Price Transparency
3个月前
已完结
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA
3个月前
已完结
皖公网安备34019202002308
